Delafloxacin meglumineFluoroquinolone antibiotic agent CAS# 352458-37-8 |
- Azelnidipine
Catalog No.:BCC4400
CAS No.:123524-52-7
- Verapamil HCl
Catalog No.:BCC4747
CAS No.:152-11-4
- Gabapentin HCl
Catalog No.:BCC4502
CAS No.:60142-95-2
- Zonisamide sodium
Catalog No.:BCC4240
CAS No.:68291-98-5
- Felodipine
Catalog No.:BCC4402
CAS No.:72509-76-3
- Manidipine
Catalog No.:BCC4404
CAS No.:89226-50-6
Quality Control & MSDS
Number of papers citing our products
Chemical structure
3D structure
| Cas No. | 352458-37-8 | SDF | Download SDF |
| PubChem ID | 11578213 | Appearance | Powder |
| Formula | C25H29ClF3N5O9 | M.Wt | 635.97 |
| Type of Compound | N/A | Storage | Desiccate at -20°C |
| Solubility | Soluble in DMSO | ||
| Chemical Name | 1-(6-amino-3,5-difluoropyridin-2-yl)-8-chloro-6-fluoro-7-(3-hydroxyazetidin-1-yl)-4-oxoquinoline-3-carboxylic acid;(2R,3R,4R,5S)-6-(methylamino)hexane-1,2,3,4,5-pentol | ||
| SMILES | CNCC(C(C(C(CO)O)O)O)O.C1C(CN1C2=C(C=C3C(=C2Cl)N(C=C(C3=O)C(=O)O)C4=NC(=C(C=C4F)F)N)F)O | ||
| Standard InChIKey | AHJGUEMIZPMAMR-WZTVWXICSA-N | ||
| Standard InChI | InChI=1S/C18H12ClF3N4O4.C7H17NO5/c19-12-13-7(1-9(20)14(12)25-3-6(27)4-25)15(28)8(18(29)30)5-26(13)17-11(22)2-10(21)16(23)24-17;1-8-2-4(10)6(12)7(13)5(11)3-9/h1-2,5-6,27H,3-4H2,(H2,23,24)(H,29,30);4-13H,2-3H2,1H3/t;4-,5+,6+,7+/m.0/s1 | ||
| General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
| About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
| Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. | ||
Delafloxacin meglumine Dilution Calculator
Delafloxacin meglumine Molarity Calculator
| 1 mg | 5 mg | 10 mg | 20 mg | 25 mg | |
| 1 mM | 1.5724 mL | 7.862 mL | 15.724 mL | 31.448 mL | 39.31 mL |
| 5 mM | 0.3145 mL | 1.5724 mL | 3.1448 mL | 6.2896 mL | 7.862 mL |
| 10 mM | 0.1572 mL | 0.7862 mL | 1.5724 mL | 3.1448 mL | 3.931 mL |
| 50 mM | 0.0314 mL | 0.1572 mL | 0.3145 mL | 0.629 mL | 0.7862 mL |
| 100 mM | 0.0157 mL | 0.0786 mL | 0.1572 mL | 0.3145 mL | 0.3931 mL |
| * Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations. | |||||
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
Description: IC50 Value: MICs ranging from 0.0078 to 0.125 micro g/ml for levofloxacin-resistant Streptococcus pneumoniae strains [1] ABT-492 was more potent against quinolone-susceptible and -resistant gram-positive organisms, had activity similar to that of ciprofloxacin against certain members of the family Enterobacteriaceae, and had comparable activity against quinolone-susceptible, nonfermentative, gram-negative organisms. in vitro: ABT-492 exhibited excellent in vitro activities against all 326 aerobic and anaerobic antral puncture sinus isolates tested with MICs (in micrograms per milliliter) at which 90% of the isolates tested were inhibited as follows: Haemophilus influenzae, 0.001; Moraxella catarrhalis, 0.008; and Streptococcus pneumoniae, 0.015 [2]. ABT-492 was as active as trovafloxacin against Chlamydia trachomatis, indicating good intracellular penetration and antibacterial activity [3]. in vivo: N/A Clinical trial: N/A
- 9-Methoxy-alpha-lapachone
Catalog No.:BCN5289
CAS No.:35241-80-6
- Benzoin methyl ether
Catalog No.:BCC8857
CAS No.:3524-62-7
- 4-(Bromomethyl)-7-methoxy coumarin
Catalog No.:BCC9202
CAS No.:35231-44-8
- Alloisoimperatorin
Catalog No.:BCN6789
CAS No.:35214-83-6
- Neobyakangelicol
Catalog No.:BCN5288
CAS No.:35214-82-5
- Ipriflavone (Osteofix)
Catalog No.:BCC5323
CAS No.:35212-22-7
- 4,5-Dimethoxy-1-cyanobenzocyclobutane
Catalog No.:BCC8665
CAS No.:35202-54-1
- AY-NH2
Catalog No.:BCC3949
CAS No.:352017-71-1
- JC-1
Catalog No.:BCC1669
CAS No.:3520-43-2
- D-Tetrahydropalmatine
Catalog No.:BCN2334
CAS No.:3520-14-7
- INCA-6
Catalog No.:BCC2462
CAS No.:3519-82-2
- Isopropylidenylacetyl-marmesin
Catalog No.:BCN6792
CAS No.:35178-20-2
- Caesalmin B
Catalog No.:BCN7252
CAS No.:352658-23-2
- 1-Chloroindan
Catalog No.:BCN2244
CAS No.:35275-62-8
- Ziyuglycoside I
Catalog No.:BCN5290
CAS No.:35286-58-9
- Ziyuglycoside II
Catalog No.:BCN5291
CAS No.:35286-59-0
- (E)-3-Hydroxy-5-methoxystilbene
Catalog No.:BCN5292
CAS No.:35302-70-6
- D-Alaninol
Catalog No.:BCC2728
CAS No.:35320-23-1
- LY 487379 hydrochloride
Catalog No.:BCC7627
CAS No.:353229-59-1
- NS 6180
Catalog No.:BCC6307
CAS No.:353262-04-1
- S26948
Catalog No.:BCC7751
CAS No.:353280-43-0
- Monocrotaline N-oxide
Catalog No.:BCN2097
CAS No.:35337-98-5
- TQS
Catalog No.:BCC7896
CAS No.:353483-92-8
- 9-Hydroxycalabaxanthone
Catalog No.:BCN5293
CAS No.:35349-68-9
Delafloxacin meglumine for the treatment of acute bacterial skin and skin structure infections (ABSSSI).[Pubmed:30539165]
Drugs Today (Barc). 2018 Nov;54(11):657-666.
Delafloxacin meglumine (Baxdela, WQ-3034, ABT-492, RX-3341; Melinta Therapeutics) was approved by the U.S. Food and Drug Administration (FDA) in June 2017 for the treatment of acute bacterial skin and skin structure infections on the basis of data from two phase III trials. Delafloxacin is a broad-spectrum anionic fluoroquinolone and its distinct chemical structure increases its potency in acidic environments. It is known to inhibit DNA replication and repair by targeting DNA gyrase and topoisomerase IV. Delafloxacin is administered via both oral and parenteral routes. It has potent activity against methicillin-resistant Staphylococcus aureus and Streptococci, and is also effective against Enterobacteriaceae and Pseudomonas aeruginosa. Delafloxacin is currently in phase III evaluation for treatment of community-acquired pneumonia and was classified as a qualified infectious disease product by the U.S. FDA in its approval.
